🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. DNL343

    Denali Therapeutics

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    2 trials

  2. DOCETAXEL, Inflectra 100 mg powder for concentrate for solution for infusion, Mycofit, 250 mg, kapsułki twarde, DOCETAXEL, INFLIXIMAB, Remsima 100 mg powder for concentrate for solution for infusion, Ceralasertib, MYCOPHENOLATE MOFETIL, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, DOCETAXEL, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. DOTAREM 0,5 mmol/mL, solution injectable, GADOPICLENOL

    Guerbet

    Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar), peripheral or abdominal/renal arteries

    phase 3 small molecule active

    1 trial

  4. DOXORUBICIN , Rinatabart Sesutecan, PACLITAXEL

    Genmab A/S

    Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresectable Endometrial Cancer

    phase 3 small molecule active

    1 trial

  5. DOXORUBICIN, EPIRUBICIN, CISPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., MITOMYCIN, LIPIODOL ULTRA FLUIDE 480 mg/ml, solution injectable, IDARUBICIN

    Ningbo Cancer Hospital

    Intermediate stage Hepatocellular carcinoma

    phase 3 small molecule active

    1 trial

  6. DOXYCYCLINE SANDOZ 100 mg, comprimé sécable, EXTENCILLINE 2,4 MUI, poudre et solvant pour suspension injectable IM

    Pari Pharma GmbH

    early syphilis

    phase 3 small molecule active

    1 trial

  7. DS-8201a

    Daiichi Sankyo

    Advanced (unresectable or metastatic) human epidermal growth receptor 2 (HER2)-expressing/HER2-mutated solid tumors

    phase 3 small molecule active

    1 trial

  8. DURVALUMAB, Savolitinib, MYCOPHENOLATE MOFETIL, Sutent 12.5 mg hard capsules, Sutent 25 mg hard capsules, Sutent 12.5 mg hard capsules, INFLIXIMAB, Sutent 25 mg hard capsules

    AstraZeneca AB

    MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  9. Danicopan

    Alexion Europe SAS

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  10. Dara SC

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  11. Daratumumab

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule active

    3 trials

  12. Daratumumab, DARATUMUMAB, LENALIDOMIDE, DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE

    Celltrion Healthcare Australia Pty Ltd

    Refractory or Relapsed Multiple Myeloma

    phase 3 small molecule active

    1 trial

  13. Darleukin, Fibromun

    Philogen S.p.A.

    Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions

    phase 3 small molecule active

    1 trial

  14. Darvadstrocel

    Takeda

    Complex Perianal Fistulas in Adult Participants With Crohn's Disease

    phase 3 mab completed

    1 trial

  15. Datopotamab deruxtecan, DOCETAXEL

    AstraZeneca AB

    TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  16. Datopotamab deruxtecan, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CAPECITABINE, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy.

    phase 3 small molecule active

    1 trial

  17. Datopotamab deruxtecan, Rilvegostomig, MYCOPHENOLATE MOFETIL, INFLIXIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    AstraZeneca AB

    Locally-advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  18. Daunoblastin 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung, Matching placebo tablets without active substance, Idarubicin Ebewe 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Quizartinib, Citarabina Hikma 100mg/5mL Soluzione Iniettabile, Quizartinib

    Daiichi Sankyo

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  19. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The nominal volume in each vial is 5.0 mL. The placebo is aseptically filled into 6R glass vials, stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan Pharma International

    Sjögren’s Syndrome With Moderate-toSevere Symptom State

    phase 3 small molecule active

    1 trial

  20. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The placebo is aseptically filled into 6R glass vials( the nominal volume in each vial is 5.0 mL) and 20R glass vials (the nominal volume in each vial is 15.0 mL) , stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan Pharma International

    Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity

    phase 3 small molecule active

    1 trial

  21. De-escalation to ticagrelor 60 mg at day 30

    COLLEGIUM PHARMACEUTICAL, INC

    Non ST Segment Elevation Acute Coronary Syndrome

    phase 3 small molecule active

    1 trial

  22. Debamestrocel - MSC-NTF (NurOwn)

    BRAINSTORM CELL THERAPEUTICS INC.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 mab active

    1 trial

  23. Decitabine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia, Adult

    phase 3 small molecule active

    1 trial

  24. Decitabine

    The First People's Hospital of Lianyungang

    Thrombocytopenia

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources